PURPOSE: To prospectively monitor progressive changes of retinal ganglion cell function in early glaucoma using the pattern electroretinogram (PERG). METHODS: Fifty-nine patients enrolled as glaucoma suspects were observed untreated over an average of 5.7±1.4 years, during which they were tested with PERG (PERGLA paradigm) and standard automated perimetry (SAP) 2 times per year. PERG amplitude and phase were normalized for physiological age-related changes, and linear regressions fitted to the data to calculate progression slopes (signal), slope SE (noise), and corresponding signal-to-noise ratios (SNR=slope÷SE). Linear regressions were also used to fit SAP global indices mean deviation (MD) and pattern standard deviation (PSD). RESULTS: On average, progression slopes of PERG amplitude/phase were skewed toward negative values, their mean being significantly (P<0.01) different from zero. In contrast, mean slopes of SAP-MD and PSD were not significantly different from zero. SNRs were higher for PERG than SAP (P<0.01). A substantial number of eyes displayed significant (P<0.05) progression of PERG amplitude (15% to 20%) or PERG phase (16% to 25%). Fewer eyes displayed significant progression of SAP-MD (0% to 2%) or SAP-PSD (4% to 8%). CONCLUSIONS: The PERG displayed clear longitudinal loss of signal (diminished amplitude, phase delay, or both) in a substantial number of eyes of patients, indicating progressive deterioration of retinal ganglion cell function. Progression of SAP global indices MD and PSD was found in a relatively smaller number of eyes. It remains to be established whether PERG progression has predictive value for developing visual dysfunction.
PURPOSE: To prospectively monitor progressive changes of retinal ganglion cell function in early glaucoma using the pattern electroretinogram (PERG). METHODS: Fifty-nine patients enrolled as glaucoma suspects were observed untreated over an average of 5.7±1.4 years, during which they were tested with PERG (PERGLA paradigm) and standard automated perimetry (SAP) 2 times per year. PERG amplitude and phase were normalized for physiological age-related changes, and linear regressions fitted to the data to calculate progression slopes (signal), slope SE (noise), and corresponding signal-to-noise ratios (SNR=slope÷SE). Linear regressions were also used to fit SAP global indices mean deviation (MD) and pattern standard deviation (PSD). RESULTS: On average, progression slopes of PERG amplitude/phase were skewed toward negative values, their mean being significantly (P<0.01) different from zero. In contrast, mean slopes of SAP-MD and PSD were not significantly different from zero. SNRs were higher for PERG than SAP (P<0.01). A substantial number of eyes displayed significant (P<0.05) progression of PERG amplitude (15% to 20%) or PERG phase (16% to 25%). Fewer eyes displayed significant progression of SAP-MD (0% to 2%) or SAP-PSD (4% to 8%). CONCLUSIONS: The PERG displayed clear longitudinal loss of signal (diminished amplitude, phase delay, or both) in a substantial number of eyes of patients, indicating progressive deterioration of retinal ganglion cell function. Progression of SAP global indices MD and PSD was found in a relatively smaller number of eyes. It remains to be established whether PERG progression has predictive value for developing visual dysfunction.
Authors: P Casas-Llera; G Rebolleda; F J Muñoz-Negrete; F Arnalich-Montiel; M Pérez-López; R Fernández-Buenaga Journal: Br J Ophthalmol Date: 2009-06-16 Impact factor: 4.638
Authors: Dawn Y Lam; Paul L Kaufman; B'Ann T Gabelt; Eleanor C To; Joanne A Matsubara Journal: Invest Ophthalmol Vis Sci Date: 2003-06 Impact factor: 4.799
Authors: Christopher Bowd; Gianmarco Vizzeri; Ali Tafreshi; Linda M Zangwill; Pamela A Sample; Robert N Weinreb Journal: Ophthalmology Date: 2009-01-22 Impact factor: 12.079
Authors: B C Chauhan; D F Garway-Heath; F J Goñi; L Rossetti; B Bengtsson; A C Viswanathan; A Heijl Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: Michael R Banitt; Lori M Ventura; William J Feuer; Eleonore Savatovsky; Gabriel Luna; Olga Shif; Brandon Bosse; Vittorio Porciatti Journal: Invest Ophthalmol Vis Sci Date: 2013-03-28 Impact factor: 4.799
Authors: Phillip S Gordon; Maja Kostic; Pedro F Monsalve; Giacinto Triolo; Luri Golubev; Gabriel Luna; Lori M Ventura; William J Feuer; Vittorio Porciatti Journal: Doc Ophthalmol Date: 2020-03-09 Impact factor: 2.379
Authors: Giedrius Kalesnykas; Ericka N Oglesby; Donald J Zack; Frances E Cone; Matthew R Steinhart; Jing Tian; Mary E Pease; Harry A Quigley Journal: Invest Ophthalmol Vis Sci Date: 2012-06-22 Impact factor: 4.799